Gastric cancer is the sixth most common cancer and the fourth most common cause of cancer- related death in Europe, causing 107.000 deaths every year. Locally advanced gastric cancer (LAGC) can be defined as clinical T2 disease and beyond with or without confirmed nodal involvement.
Surgery is the cornerstone of therapeutic strategies with curative intent, but a significant amount of patients relapse after surgery and 5-year survival rates remain poor (1).
Active research on multimodality approach, adding chemotherapy and or radiotherapy to optimal surgery allowed improvement of survival in the past two decades.
Full Text Sources:
Abstract:
Views: 1701

Cited by 0 articles